Register Login

AVALO THERAPEUTICS, INC. (AVTX)

Doyle Mittie 🟡 adjusted position in 25.5K shares (2 derivative) of Avalo Therapeutics, Inc. (AVTX) at $16.15 ($1.0M) Transaction Date: Mar 16, 2026 | Filing ID: 000004

Full text
Register to leave comments
  • News bot March 18, 2026, 8:08 p.m.

    🔍 Doyle Mittie (Executive)

    Company: Avalo Therapeutics, Inc. (AVTX)

    Report Date: 2026-03-16

    Transaction Summary:

    • Total transactions: 5
    • Derivative instruments: 2
    • Holdings reported: 0
    • Total shares acquired: 25,492
    • Total shares sold: 50,984

    Detailed Transactions and Holdings:

    • Acquired 19,500 shares of Common Stock at $12.65 per share (Direct)
      Date: 2026-03-16 | Code: M | equity_swap_involved: 0 | shares_owned_after: 23,122.00 | transaction_form_type: 4
    • Acquired 5,992 shares of Common Stock at $8.04 per share (Direct)
      Date: 2026-03-16 | Code: M | equity_swap_involved: 0 | shares_owned_after: 29,114.00 | transaction_form_type: 4
    • Sold 25,492 shares of Common Stock at $16.1465 per share (Direct)
      Date: 2026-03-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,622.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 19,500 shares of Stock Option (Right to Buy) at $12.65 per share (Derivative)
      Date: 2026-03-16 | Code: M | Expires: 2034-07-15 | equity_swap_involved: 0 | shares_owned_after: 214,500.00 | transaction_form_type: 4 | Footnotes: F2
    • Sold 5,992 shares of Stock Option (Right to Buy) at $8.04 per share (Derivative)
      Date: 2026-03-16 | Code: M | Expires: 2035-01-28 | equity_swap_involved: 0 | shares_owned_after: 149,008.00 | transaction_form_type: 4 | Footnotes: F3

    Footnotes:

    • F1: The reported securities were sold in multiple transactions at prices ranging from $16.00 to $16.34. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
    • F2: The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
    • F3: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Search

News categories